Mirati appoints EVP and chief business officer
Prior to joining Mirati, Mr. LeMasters served as the CEO of Promosome, a privately held biotherapeutics and biosimilars company.
Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company.
Mr. LeMasters also served as co-founder and chief business officer of Cabrellis Pharmaceuticals, Inc., where he negotiated its acquisition by Pharmion Corporation, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC.
Mr. LeMasters also worked in the corporate business development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas.
Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning.
Mr. LeMasters currently serves as a board member of Aarden Pharmaceuticals, where he is also a co-founder, and as a board member of the Hoosier Cancer Research Network, a clinical research organization. ■
LATEST MOVES FROM California
- Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
- Endologix appoints John Onopchenko as COO
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
More inside POST